solute carrier family 2 member 7Genealiases: GLUT-7 · GLUT7 · hGLUT7
Q-omics provides the consensus-scored SLC2A7 profile across patient tissues and cancer cell-line models. SLC2A7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SLC2A7 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, SLC2A7 RNA expression shows 9,163 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KIRC, and TGCT as cancer lineages where SLC2A7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC2A7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC2A7 survival associations across molecular data types. SLC2A7 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC2A7 RNA expression–survival associations across cancer types. High SLC2A7 expression shows unfavorable associations in UCEC, MESO, ACC, LUAD and LGG, but favorable associations in SCLC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for SLC2A7 RNA expression.
This table summarizes SLC2A7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SLC2A7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC2A7 shows lower tumor expression in KICH, STAD and PAAD and higher tumor expression in KIRC, HNSC and LIHC. The KIRC box plot shows higher SLC2A7 RNA expression in tumor versus normal tissue (log2 FC = +0.305, t-test p < 0.001).
This table shows molecular features associated with SLC2A7 in patient tissues and cancer cell lines. In patient samples, SLC2A7 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC2A7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
